UnifAI's AI Digital Reader gains Special Use Authorisation from MHRA for COVID-19 lateral flow tests
Updated: Feb 9
UnifAI Technology is delighted to announce that our AI powered Digital Reader has gained Special Use Authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) to use UnifAI's cutting edge artificial intelligence to accurately read and record COVID-19 lateral flow tests.
The Digital Reader is a flexible remote diagnostic capability which uses advanced AI to turn otherwise analogue and siloed lateral flow and other point of care tests into connected and digital tests, providing auditable and evidence-based results. UnifAI is developing it for use with human and animal point of care health testing, and for in-field environmental monitoring such as for water and soil quality. We believe it to be the most accurate such capability on the market today.
UnifAI today published the following press release:
U.K., Europe and USA , 14 January 2022: UnifAI Technology Limited, a UK based AI company, today announces that the Medicines & Healthcare products Regulatory Agency (“MHRA”) has authorised for Special Use the UnifAI Technology Digital Reader as a medical device for the accurate reading of COVID-19 lateral flow diagnostic tests. The Special Use derogation currently covers Innova, ACON and Orient Gene and MP Bio lateral flow tests. Further tests expected to be added.
The UnifAI Technology Digital Reader uses a proprietary Deep Learning AI capability in combination with users’ smartphone cameras, and has demonstrated to read Lateral Flow Tests more accurately than the human eye in tests.
About the UnifAI Technology Digital Reader:
The Digital Reader uses a transparent and “explainable” AI, which can demonstrate auditable outputs for every test, enabling key stakeholders such as UKHSA and the regulators to see that performance is delivered as intended. UnifAI Technology is partnered with AWS and the solution is hosted in AWS cloud services, giving it virtually limitless scalability automatically and on-demand.
The Digital Reader was developed by UnifAI Technology with support from InnovateUK, the UK’s innovation agency which provides support and funding to exciting British based companies developing cutting edge solutions to solve real-world problems in the UK and overseas.
About UnifAI Technology:
UnifAI Technology is an artificial intelligence company whose vision is to simplify artificial intelligence for real world applications and has focus on using its AI to improve the health and well being of people, the environment, and infrastructure.
Simon Edmonds, Chief Business Officer, Innovate UK said:
“When the global pandemic hit, it was clear that smart innovations were needed to address the new realities. Innovate UK sought out the best ideas and has funded projects such as UnifAI’s lateral flow test digital reader. This technology, now authorised by the MHRA, will make Covid testing more accurate. This will bring real benefits as we seek to beat this pandemic and shows the value of backing enterprising ideas.”
Phil Hughes, Chairman and CEO of UnifAI Technology, said:
“It is a major achievement to create what has been described as the best-in-class AI capability to interpret Lateral Flow Device results. The UnifAI Technology Digital Reader can be used to help reduce transmission of the virus and reduce the impact of COVID-19 on people and the economy. This capability has wider applicability beyond COVID and can be used to help improve remote diagnostics for a range of health conditions. This will become increasingly important in the developed and developing world as we face new healthcare challenges with growing global populations and increased pressure on resources and supply chains. We aim to play our part in helping to improve the health and wellbeing of people by using our AI as a force for good in real world applications, as we have done with the UnifAI Technology Digital Reader.”